.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 4,885,304

« Back to Dashboard

Details for Patent: 4,885,304

Title: Mitomycin analogs
Abstract:Compounds of the formula, I, ##STR1## wherein: Y is hydrogen or lower alkyl; and X is a thiazolamino radical, a furfurylamino radical or a radical of the formula, ##STR2## in which R, R.sup.1, and R.sup.2 are the same or different and selected from the group consisting of hydrogen and lower alkyl, and R.sup.3 is selected from the group consisting of lower alkenyl, halo-lower alkenyl, lower alkynyl, lower akloxycarbonyl, thienyl, formamyl, tetrahydrofuryl and benzene sulfonamide. Also disclosed are novel methods for treatment of neoplastic disease states in animals, which methods comprise administering a therapeutically effective amount of a compound of the formula, Ia, ##STR3## wherein, Y is hydrogen or lower alkyl; and Z is a thiazolamino radical, a furfuryllamino radical, a cyclopropylamino radical, a pyridylamino radical, or a radical of the formula, ##STR4## in which R.sup.4, R.sup.5, and R.sup.6 are the same or different and selected from the group consisting of hydrogen and lower alkyl, and R.sup.7 is selected from the group consisting of lower alkenyl, halo-lower alkenyl, lower alkynyl, lower alkoxycarbonyl, halo-lower alkyl, hydroxy-lower alkyl, pyridyl, thienyl, formamyl, tetrahydrofuryl, benzyl, and benzene sulfonamide.
Inventor(s): Remers; William A. (Tucson, AZ)
Assignee: University Patents, Inc. (Westport, CT)
Filing Date:Jul 11, 1984
Application Number:06/629,814
Claims:1. A method for treatment of a neoplastic disease state in an animal comprising administering to an animal having such a disease a therapeutically effective amount of a compound of the formula, ##STR11## wherein: Z is selected from the group consisting of: a pyridylamino; or the formula, ##STR12## in which R.sup.4, R.sup.5, and R.sup.6 are the same or different and selected from the group consisting of hydrogen or lower alkyl and R.sup.7 is halo lower alkyl.

2. The method according to claim 1 wherein the compound is selected from the group consisting of:

1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methyl-6-(3-pyridyl amino)-azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate;

1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-1,5-dimethyl-6-(2-chl oroethylamino)-azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate;

1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methyl-6-(2-chloroe thylamino]-azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate; and

1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methyl-6-(2-chlorop ropylamino)-azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate.

3. The method according to claim 1 wherein the amount of the compound administered comprises a daily dose of from approximately 0.2 mg to approximately 51.2 mg per kilogram of the body weight of the animal.

4. A pharmaceutical composition for use in treatment of a neoplastic disease state in an animal, said composition comprising a pharmaceutically acceptable diluent, adjuvant or carrier and, as the active ingredient, from approximately 0.001 to approximately 5 mg of a compound of the formula: ##STR13## wherein: Y is hydrogen or lower alkyl and Z is selected from the group consisting of the formula, ##STR14## in which R.sub.4, R.sub.5 and R.sub.6 are the same or different and selected from the group consisting of hydrogen or lower alkyl and R.sub.7 is halo lower alkyl.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc